natgillin/translations-raw huggingface dataset:
the binder is selected from the group consisting of pre-gelatinized starch, sodium carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinyl pyrrolidone, copolyvidone, gelatin, natural gums, starch paste, sucrose, corn syrup, polyethylene glycols and sodium alginate; and the lubricant is selected from the group consisting of hydrogenated vegetable oil, calcium stearate, and glyceryl behenate. 
vezivo je odabrano iz skupine koja sadrži preželatinizirani škrob, natrijevu karboksimetil celulozu, hidroksipropil celulozu, hidroksipropil metil celulozu, polivinil pirolidon, kopolividon, želatinu, prirodne gume, škrobnu pastu, sukrozu, kukuruzni sirup, polietilen glikole i natrijev alginat; i lubrikant je odabran iz skupine koja sadrži hidrogenirano biljno ulje, kalcijev stearat, te gliceril behenat.
the water-insoluble filler is microcrystalline cellulose; 
punilo netopivo u vodi je mikrokristalna celuloza;
an adjuvant component, comprising or consisting of at least one (m)RNA complexed with a polycationic compound which is a polycationic peptide or protein, wherein the N/P ratio in the adjuvant component is in the range of 0.3-4, as a first component, and 
komponentu adjuvanta, koja obuhvaća ili se sastoji od barem jedne (m)RNK kompleksirane s polikationskim spojem koji je polikationski peptid ili protein, pri čemu je omjer N/P u komponenti adjuvanta u rasponu od 0.3-4, kao prve komponente, te
as a second component, at least one free mRNA encoding at least one antigen, wherein the immunostimulatory composition is capable to elicit or enhance an innate and an adaptive immune response in a mammal and wherein the molar ratio of the (m)RNA of the adjuvant component a) to the at least one free mRNA of the second component b) is in the range from 0.1:1 to 1:0.01. 
kao drugu komponentu, barem jednu slobodnu mRNK koja kodira barem jedan antigen, naznačen time da je imunostimulacijski pripravak u stanju izazvati ili poboljšati prirođeni i prilagodljiv imunološki odgovor kod sisavca i pri čemu molarni omjer (m)RNK iz komponente adjuvanta a) prema barem jednoj slobodnoj mRNK od druge komponente b) je u rasponu od 0.1:1 do 1:0.01.
Immunostimulatory composition according to claim 1, wherein the at least one (m)RNA of the adjuvant component, is selected from a short RNA oligonucleotide, a coding RNA, including an mRNA, an immunostimulatory RNA, an siRNA, an antisense RNA, or riboswitches, ribozymes or aptamers. 
Imunostimulacijski pripravak prema zahtjevu 1, naznačen time da je barem jedna (m)RNK iz komponente adjuvanta, odabrana od kratkog oligonukleotida RNK, kodirajuće RNK, uključujući mRNK, imunostimulacijsku RNK, siRNK, antisense RNK, ili ribookidače, ribozime ili aptamere.
Immunostimulatory composition according to claims 1 or 2, wherein the at least one (m)RNA of the adjuvant component is an mRNA. 
Imunostimulacijski pripravak prema zahtjevima 1 ili 2, naznačen time da barem jedna (m)RNK iz komponente adjuvanta je mRNK.
Immunostimulatory composition according to any of claims 1 to 3, wherein the at least one free mRNA and the at least one (m)RNA of the adjuvant component are identical to each other. 
Imunostimulacijski pripravak prema bilo kojem zahtjevu od 1 do 3, naznačen time da su barem jedna slobodna mRNK i barem jedna (m)RNK iz komponente adjuvanta međusobno identične.
Immunostimulatory composition according to any of claims 1 to 3, wherein the at least one free mRNA and the at least one (m)RNA of the adjuvant component are different from each other. 
Imunostimulacijski pripravak prema bilo kojem zahtjevu od 1 do 3, naznačen time da su barem jedna slobodna mRNK i barem jedna (m)RNK iz komponente adjuvanta međusobno različite.
Immunostimulatory composition according to any of claims 1 to 7, wherein the at least one free mRNA and/or the at least one (m)RNA of the adjuvant component are GC-stabilized. 
Imunostimulacijski pripravak prema bilo kojem zahtjevu od 1 do 7, naznačen time da su barem jedna slobodna mRNK i/ili barem jedna (m)RNK iz komponente adjuvanta GC-stabilizirane.
Immunostimulatory composition according to claim 8, wherein the G/C content of the coding region of the GC-stabilized RNA is increased compared with the G/C content of the coding region of the native RNA, the coded amino acid sequence of the GC-stabilized modified (m)RNA not being altered compared with the encoded amino acid sequence of the native modified (m)RNA. 
Imunostimulacijski pripravak prema zahtjevu 8, naznačen time da G/C sadržaj kodirajuće regije GC-stabilizirane RNK je povećan u usporedbi sa G/C sadržajem kodirajuće regije prirodne RNK, kodirana sekvenca aminokiseline GC-stabilizirane modificirane (m)RNK nije izmijenjen u usporedbi sa kodiranom sekvencom aminokiseline prirodne modificirane (m)RNK.
preparing the adjuvant component, comprising or consisting of the at least one (m)RNA complexed with a polycationic compound which is a polycationic peptide or protein, by mixing the at least one (m)RNA with the cationic or polycationic compound which is a polycationic peptide or protein such that the N/P ratio in the adjuvant component is in the range of 0.3-4; and 
pripravu komponente adjuvanta, koja obuhvaća ili se sastoji od barem jedne (m)RNK kompleksirane sa polikationskim spojem koji je polikationski peptid ili protein, pomoću miješanja barem jedne (m)RNK sa kationskim ili polikationskim spojem koji je polikationski peptid ili protein tako da je omjer N/P u komponenti adjuvanta u rasponu od 0.3-4; i
preparing an adjuvant component comprising or consisting of at least one (m)RNA, complexed with a polycationic compound which is a polycationic peptide or protein, by mixing in a specific ratio the at least one (m)RNA and a polycationic compound as defined according to any of claims 1 to 12; and 
pripravu komponente adjuvanta koja obuhvaća ili se sastoji od barem jedne (m)RNK, kompleksirane sa polikationskim spojem koji je polikationski peptid ili protein, miješanjem u specifičnom omjeru barem jedne (m)RNK i polikationskog spoja kako je definirano u bilo kojem zahtjevu od 1 do 12; i
an adjuvant component, comprising or consisting of at least one (m)RNA, complexed with a polycationic compound which is a polycationic peptide or protein, as a first component, and 
komponente adjuvanta, koja obuhvaća ili se sastoji od barem jedne (m)RNK, kompleksirane sa polikationskim spojem koji je polikationski peptid ili protein, kao prve komponente, i
A compound of formula (I), or a pharmaceutically acceptable salt thereof: 
Kombinacija spoja formule (I), ili njegove farmaceutski prihvatljive soli:
A compound according to claim 1 having the structure: 
Kombinacija prema patentnom zahtjevu 1 pri čemu spoj formule (I) ima strukturu:
R'5 is an optionally substituted heteroaryl; 
R'5 je opcionalno supstituirani heteroaril;
p, for each occurrence, is independently 1 or 2; with the proviso that the compound is not 
p, u svakoj pojavljivanju, je nezavisno 1 ili 2; uz uvjet da spoj nije
The compound of Claim 7, wherein R'5 is represented by the following formula: wherein: 
Spoj zahtjeva 7, gdje je R'5 predstavljen slijedećom formulom: [image] gdje:
The compound of Claim 1, wherein the compound is 
Spoj zahtjeva 1, gdje je spoj
Ry is an optionally substituted alkyl. 
Ry je opcionalno supstituirani alkil.
The compound of Claim 5, wherein the compound is selected from the group consisting of 
Spoj zahtjeva 5, pri čemu je spoj izabran iz skupine koje se sastoji od
The compound of Claim 7, wherein the compound is selected from the group consisting of 
Spoj zahtjeva 7, pri čemu je spoj izabran iz skupine koja se sastoji od
A compound of any one of Claims 1 through 9 for use in inducing degradation of a c-kit, Bcr-Abl, FLT3, or EGFR, protein; inhibiting topoisomerase II; or modulating the activity of glucocorticoid receptors. 
Spoj bilo kojeg od zahtjeva 1 do 9 za uporabu u induciranju degradacije c-set, Bcr-Abl, FLT3, ili EGFR, proteina; inhibiranju topoizomeraze II; ili moduliranju aktivnosti glukokortikoid receptora.
The use of a compound of any one of Claims 1 through 9 for the manufacture of a medicament for inducing degradation of a c-kit, Bcr-Abl, FLT3, or EGFR, protein; inhibiting topoisomerase II; or modulating the activity of glucocorticoid receptors. 
Uporaba spoja bilo kojeg od zahtjeva 1 do 9 za proizvodnju lijeka za induciranje degradacije c-set, Bcr-Abl, FLT3, ili EGFR, proteina; inhibiranje topoizomeraze II; ili moduliranje aktivnosti glukokortikoid receptora.
A compound of any one of Claims 1 through 9 for use in treating a c-kit, Bcr-Abl, FLT3, or EGRF associated cancer; a B-cell or T-cell non-Hodgkin's lymphoma; treating or inhibiting angiogenesis; or blocking, occluding, or otherwise disrupting blood flow in neovasculature in a mammal. 
Spoj bilo kojeg od zahtjeva 1 do 9 za uporabu u liječenju raka povezanog sa c-set, Bcr-Abl, FLT3, ili EGFR; B-stanice ili T-stanice non-Hodgkinove limfome; liječenju ili inhibiranju angiogeneze; ili blokiranju, zatvaranju ili na neki drugi način remećenju protoka krvi u neovaskulaturi u sisavca.
The use of a compound of any one of Claims 1 through 9 for the manufacture of a medicament for use in treating a c-kit, Bcr-Abl, FLT3, or EGRF associated cancer; a B-cell or T-cell non-Hodgkin's lymphoma; treating or inhibiting angiogenesis; or blocking, occluding, or otherwise disrupting blood flow in neovasculature in a mammal. 
Uporaba spoja bilo kojeg od zahtjeva 1 do 9 za proizvodnju lijeka za uporabu u liječenju raka povezanog sa c-set, Bcr-Abl, FLT3, ili EGFR; B-stanice ili T-stanice non-Hodgkinove limfome; liječenju ili inhibiranju angiogeneze; ili blokiranju, zatvaranju ili na neki drugi način remećenju protoka krvi u neovaskulaturi u sisavca.
An oil dispersion comprising: 
Uljna disperzija naznačena time da sadrži:
from 40 to 90 % oil by weight; 
od 40 do 90 % težinski ulja;
from 0 to 40 % other active ingredients by weight; 
od 0 do 40 % težinski drugih aktivnih sastojaka;
An oil dispersion according to claim 2, wherein the 2-benzoyl-1,3-cyclohexanedione herbicide is mesotrione or tembotrione. 
Uljna disperzija prema zahtjevu 2, naznačena time da herbicid 2-benzoil-1,3-cikloheksandion je mezotrion ili tembotrion.
An oil dispersion according to claim 3, wherein the 2-benzoyl-1,3-cyclohexanedione herbicide is mesotrione. 
Uljna disperzija prema zahtjevu 3, naznačena time da herbicid 2-benzoil-1,3-cikloheksandion je mezotrion.
An oil dispersion according to any one of the previous claims, in which the acid is an inorganic acid. 
Uljna disperzija prema bilo kojem od prethodnih zahtjeva, naznačena time da kiselina je anorganska kiselina.
An oil dispersion according to any one of the previous claims, in which the inorganic acid is phosphoric acid. 
Uljna disperzija prema bilo kojem od prethodnih zahtjeva, naznačena time da anorganska kiselina je fosforna kiselina.
An oil dispersion according to any one of the previous claims, in which the acid is a carboxylic acid. 
Uljna disperzija prema bilo kojem od prethodnih zahtjeva, naznačena time da kiselina je karboksilna kiselina.
An oil dispersion according to any one of the previous claims, in which the content of the inorganic acid or the carboxylic acid is from 0.2 to 2 % by weight. 
Uljna disperzija prema bilo kojem od prethodnih zahtjeva, naznačena time da je udio anorganske kiseline ili karboksilne kiseline od 0.2 do 2 % težinski.
An oil dispersion according to any one of the previous claims, in which the acid is an acidic surfactant. 
Uljna disperzija prema bilo kojem od prethodnih zahtjeva, naznačena time da kiselina je kiseli surfaktant.
An oil dispersion according to claim 14 or claim 15, in which the content of the acidic surfactant is from 1 to 40 % by weight. 
Uljna disperzija prema zahtjevu 14 ili zahtjevu 15, naznačena time da je udio kiselog surfaktanta od 1 do 40 % težinski.
A process for producing an organic amine salt of 6-fluoro-3-hydroxy-2-pyrazinecarbonitrile according to claim 1, which comprises reacting 3,6-difluoro-2-pyrazinecarbonitrile with water in the presence of a base, and then forming a salt with an organic amine, wherein the organic amine is dicyclohexylamine. 
Postupak za proizvodnju organske aminske soli 3-hidroksi-2-pirazinkarbonitrila u skladu s patentnim zahtjevom 1, naznačen time, da se sastoji od reakcije 3,6-difluoro-2-pirazinkarbonitrila s vodom u nazočnosti lužine, a potom formiranja soli s organskim aminom, pri čemu je organski amin dicikloheksilamin.
A process for the preparation of a polymer conjugate of an indolocarbazole compound of formula (I) wherein 
Postupak za pripremu polimernog konjugata spoja indolokarbazola formule (I) [image] gdje
and R2 are the same or a different residue and are each independently selected from the group consisting of: 
i R2 su isti ili različiti ostatak i svaki od njih je nezavisno izabran iz grupe koju čine:
-CO(CH2)jR4, wherein j is 1 to 6, and R4 is selected from the group consisting of 
-CO(CH2)jR4, gdje je 1 do 6, i R4 je izabran iz grupe koju čine
-SR7, wherein R7 is selected from the group consisting of hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, -(CH2)aCO2R10 (wherein a is 1 or 2, and wherein R10 is selected from the group consisting of hydrogen and substituted or unsubstituted lower alkyl) and - (CH2)aCO2NR5R6, 
-SR7, gdje R7 je izabran iz grupe koju čine vodik, supstituiran ili nesupstituiran niži alkil, supstituiran ili nesupstituiran niži alkenil, supstituiran ili nesupstituiran niži alkinil, supstituiran ili nesupstituiran aril, supstituiran ili nesupstituiran heteroaril, supstituiran ili nesupstituiran aralkil, -(CH2)äCO2R10 (gdje a je 1 ili 2, i gdje R10 je izabran iz grupe koju čine vodik i supstituiran ili nesupstituiran niži alkil) i -(CH2)aCO2NR5R6,
is hydrogen, halogen, acyl, carbamoyl, substituted or unsubstituted lower alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted lower alkynyl or amino, whereby the term "lower alkyl", when used alone or in combination with other groups, refers to a straight chained or branched lower alkyl group containing from 1-6 carbon atoms; 
je vodik, halogen, acil, karbamoil, supstituiran ili nesupstituiran niži alkil, supstituiran ili nesupstituiran alkenil, supstituiran ili nesupstituiran niži alkinil ili amino; pri čemu se termin se "niži alkil", kada je korišten pojedinačno ili u kombinaciji sa drugim grupama, odnosi na ravnolančanu ili razgranatu nižu alkil grupu koja sadrži od 1-6 atoma ugljika;
the term "lower alkenyl" refers to C2-C6 alkenyl groups which may be straight chained or branched and may be in the Z or E form; 
termin "niži alkenil" označava C2-C6 alkenil grupe koje mogu biti ravnolančane ili razgranate i mogu biti u Z ili E obliku;
The process according to anyone of claims 1 to 2, wherein the process is carried out in an organic solvent, preferably in a anhydrous organic solvent, selected from the group of dichloromethane, chloroform and N,N -dimethylformamide or wherein the process is carried out under inert gas atmosphere, preferably under nitrogen or argon atmosphere. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 2, naznačen time što se postupak izvodi u organskom otapalu, poželjno u anhidriranom organskom otapalu, izabranom iz grupe koju čine diklorometan, kloroform i N,N-dimetilformamid ili što se postupak izvodi pod inertnom atmosferom plina, poželjno pod atmosferom dušika ili argona.
The process according to any one of the preceding claims, wherein the polymer conjugate compound of formula (I) is directly obtained by chromatographic purification, wherein the purification of the polymer conjugate compound of formula (I) preferably is performed in a solvent, preferably selected from dichloromethane, water, methanol, acetonitrile, ammonium formate buffer solution at different mixture ratios. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što je spoj konjugat polimera formule (I) direktno dobijen kromatografskim pročišćavanjem, pri čemu se pročišćavanje spoja konjugata polimera formule (I) poželjno izvodi u otapalu, poželjno izabranom od diklorometana, vode, metanola, acetonitrila, puferske otopine amonijeva formiata u različitim proporcijama smjese.
a mPEG with an average molecular weight of about 500 to about 10000 Da, e.g. 
mPEG sa prosječnom molekularnom masom od oko 500 do oko 10000 Da, npr.
or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, W1 and W2 are preferably hydrogen, and wherein the polymer X preferably is a (polyethylene) glycol, e.g. 
ili njegova farmaceutski prihvatljiva sol, gdje R1, R2, R3, W1 i W2 su poželjno vodik, i gdje polimer X je poželjno (polietilen) glikol, npr.
an mPEG with an average molecular weight of about 500 to about 10000 Da, e.g. 
mPEG sa prosječnom molekularnom masom od oko 500 do oko 10000 Da, npr.
for topical applications, or for systemic applications, e.g. 
za topikalne primjene, ili za sustavne primjene, npr.
in the prevention, alleviation and/or treatment of neurological disorders, neuropathies and neurodegenerative disorders of the central and peripheral nervous system, 
u prevenciji, ublažavanju i/ili liječenju neuroloških poremećaja, neuropatija i neurodegenerativnih poremećaja središnjeg i perifernog živčanog sustava,
in the prevention, alleviation or/and treatment of NGF-related pain and hyperalgesia, 
u prevenciji, ublažavanju i/ili liječenju bolova povezanih sa NGF i hiperalgezije,
in the prevention, alleviation and/or treatment of Behçet's disease, Sjogren's syndrome, vasculitis, uveitis, retinopathies. 
u prevenciji, ublažavanju i/ili liječenju Behçet-ove bolesti, Sjogren-ovog sindroma, vaskulitisa, uveitisa, retinopatija.
The polymer conjugate for use according to claim 16, wherein the dermal pathologies are psoriasis, atopic dermatitis, chronic eczema, acne, pitiriasis rubra pilaris, keloids, hypertrophic scars and skin tumors, and wherein the dermal pathology particularly is psoriasis. 
Polimerni konjugat za uporabu prema patentnom zahtjevu 16, naznačen time što dermalne patologije su psorijaza, atopijski dermatitis, kronični ekcem, akne, pitiriazis rubra pilaris, keloidi, hipertrofični ožiljci i tumori kože, i pri čemu dermalna patologija je posebno psorijaza.
The polymer conjugate for use according to claim 17 for topical administration, particularly in the form of liposomes. 
Polimerni konjugat za uporabu prema patentnom zahtjevu 17 za topikalnu primjenu, posebno u obliku lipozoma.
A benzodiazepine compound represented by General Formula (1) or a salt thereof according to claim 4, which is selected from the group consisting of the following compounds: 
Spoj benzodiazepina predstavljen općom formulom (1) ili njegova sol, prema zahtjevu 4, naznačen time, da je odabran iz skupine koja se sastoji od sljedećih spojeva:
A pharmaceutical composition comprising a benzodiazepine compound represented by Formula (1) or a salt thereof according to any of claims 1 to 7, and a pharmacologically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj benzodiazepina predstavljenog općom formulom (1) ili njegovu sol, prema bilo kojem zahtjevu od 1 do 7, i farmakološki prihvatljiv nosač.
an insulation portion comprising an electrically insulating material (17) covering a portion of the wire (14); and a handle (19) fixedly engaging at least a portion of the lead section, 
izolacijski komad koji sadrži električni izolacijski materijal (17) koji pokriva komad žice (14); i ručku (19) čvrsto spojenu barem s jednim odsječkom dovodnog ušća;
The capsularhexis device (10) of claim 1, wherein the superelastic wire (14) is formed from a nickel titanium alloy. 
Naprava za kapsuloreksu (10) prema zahtjevu 1, naznačena time, da je visokoelastična žica (14) oblikovana od legure nikla i titana.
The capsularhexis device (10) of claim 4, wherein the superelastic wire (14) has a rectangular cross section around at least substantially the entire loop, and wherein the thermally insulating layer (55) is disposed on three sides of the superelastic wire (14) around at least substantially the entire loop. 
Naprava za kapsuloreksu (10) prema zahtjevu 4, naznačena time, da visokoelastična žica (14) ima pravokutni poprečni presjek oko barem značajno većeg dijela od cijelog koluta, te je pritom raspoređen toplinsko-izolacijski sloj (55) na tri strane od visokoelastične žice (14) oko barem značajno većeg dijela od cijelog koluta.
Solubilisation of crystalline or amorphous rifaximin, or their mixture, in organic solvents or their mixtures; 
otapanje kristalnog ili amorfnog rifaksimina, ili njihove smjese, u organskim otapalima ili njihovim smjesama;
Rifaximin powder obtained by a process of claim 1 having an X-Ray diffraction spectrum corresponding to an amorphous form and having a particle size between 40 and 120 micrometers in a percentage of 90% of the total particles as determined by using a Beckman-Coulter LS 100 Q particle size analyzer equipped with a micro-volume cell, and a bulk density between 0.1 and 0.50 g/ml as determined by using a 10 ml volumetric flask. 
Rifaksimin u prahu koji je dobiven postupkom prema zahtjevu 1 naznačen time da ima spektar rendgenske difrakcije koji odgovara amorfnom obliku i koji ima veličinu čestica između 40 i 120 mikrometara u postotcima od 90% ukupnog broja čestica kao što je određeno pomoću Beckman-Coulter LS 100 Q par analizatora veličine čestica opremljenog s mikro-volumenskom ćelijom, te nasipnu gustoću između 0.1 i 0.50 g/ml kao što je određeno pomoću 10 ml volumetrijske tikvice.
The pharmaceutical composition according to claim 5 or 6 in form of tablets comprising one or more of disintegrants, diluents, sweeteners, plasticizers, anti-agglomeration agents, anti-sticking agents, glidants, ligant, and optionally colouring, buffering, flavouring and sweetening agents. 
Farmaceutski pripravak prema zahtjevu 5 ili 6 u obliku tableta naznačen time da sadrži jedno ili više sredstava za razgradnju, sredstava za razrjeđivanje, zaslađivača, omekšivača, anti-aglomeracijskih sredstava, sredstva protiv ljepljenja, sredstva za pospješivanje klizanja, sredstva za vezanje, te proizvoljno sredstva za bojanje, pufer, sredstva za okus i zaslađivače.
The pharmaceutical composition according to claim 8 in the form of tablets having the following composition: 
Farmaceutski pripravak prema zahtjevu 8 u obliku tableta naznačen time da ima slijedeći sastav:
lubrication of the obtained granulate; 
podmazivanje dobivenog granulata;
tabletting the granulate of step b) with pharmaceutically acceptable excipients; 
tabletiranje granulata iz koraka b) sa farmaceutski prihvatljivim pomoćnim tvarima;
The aqueous formulation of claim 1 comprising an analogue of exendin-4 selected from a group comprising lixisenatide, exenatide and liraglutide. 
Vodena formulacija u skladu s patentnim zahtjevom 1, naznačena time što sadrži analog eksendina-4, kojeg se bira iz skupine koju čine liksisenatid, eksenatid i liraglutid.
The aqueous formulation of claim 2 comprising 0.1 µg to 10 µg lixisenatide per U insulin glargine. 
Vodena formulacija u skladu s patentnim zahtjevom 2, naznačena time što sadrži 0,1 µg do 10 µg liksisenatida po jedinici inzulin glargina.
Polypeptide derivative according to claim 8 to 10, which is a recombinant polypeptide wherein the amino acid sequence of each of said molecule(s) suitable for eliciting an immune response is inserted into a permissive site of the adenylate cyclase amino acid sequence of the mutant polypeptide, thereby preserving the capacity of said mutant polypeptide to translocate its N-terminal adenylate cyclase enzyme domain into target cells. 
Polipeptidni derivat prema bilo kojem od zahtjeva 8 do 10, koji je rekombinantni polipeptid gdje je aminokiselinska sekvenca svake od molekula prikladnih za izazivanje imunog odgovora umetnuta na dopustivo mjesto tog polipetida, uz uvjet očuvanja sposobnosti tog polipeptida da premjesti svoju N-terminalnu domenu enzima adenilat ciklaze u stanice koje proizvode CD11b/CD18.